Does Magnesium Stress Randomized Trial work?

Updated June 2026

Quick Answer

Magnesium Stress Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: This review synthesizes current evidence and provides context for an ongoing cluster-randomized trial that is testing whether a center-wide dialysate magnesium concentration of 0.75 mmol/L, versus ≤0.50 mmol/L, delivered as a policy and sustained for up to four years, reduces the risk of major cardiovascular-related hospitalizations.

Key Takeaways

  • 01This review synthesizes current evidence and provides context for an ongoing cluster-randomized trial that is testing whether a center-wide dialysate magnesium concentration of 0.75 mmol/L, versus ≤0.50 mmol/L, delivered as a policy and sustained for up to four years, reduces the risk of major cardiovascular-related hospitalizations. [Tannar B (2026)]
  • 02Systematic reviews and meta-analyses show that hypomagnesemia is associated with higher risks of cardiovascular events and all-cause mortality in hemodialysis. [Tannar B (2026)]
  • 03Given encouraging but predominantly surrogate-based evidence, adequately powered randomized trials are warranted. [Tannar B (2026)]
  • 04Purpose of review Cardiovascular disease (CVD) accounts for nearly half of deaths among people receiving maintenance hemodialysis. [Tannar B (2026)]
The current Migaku evidence database contains 2 reusable source documents for Magnesium Stress Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - This review synthesizes current evidence and provides context for an ongoing cluster-randomized trial that is testing whether a center-wide dialysate magnesium concentration of 0.75 mmol/L, versus ≤0.50 mmol/L, delivered as a policy and sustained for up to four years, reduces the risk of major cardiovascular-related hospitalizations. [Tannar B (2026); evidence level 4] - Systematic reviews and meta-analyses show that hypomagnesemia is associated with higher risks of cardiovascular events and all-cause mortality in hemodialysis. [Tannar B (2026); evidence level 4] - Given encouraging but predominantly surrogate-based evidence, adequately powered randomized trials are warranted. [Tannar B (2026); evidence level 4] - Purpose of review Cardiovascular disease (CVD) accounts for nearly half of deaths among people receiving maintenance hemodialysis. [Tannar B (2026); evidence level 4] - Although Mg is frequently discussed as an analgesic supplement, emerging evidence suggests that it acts as a neurovascular-metabolic modulator. [Yoon Y (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Effects of Increasing the Concentration of Dialysate Magnesium on Cardiovascular Health: A Narrative Review.
  2. Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain.